Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced that senior management will present the Company's pipeline program exploring the treatment of glaucoma at the Glaucoma 360 New Horizons Forum 2025 on Friday, February 7, 2025, in San Francisco, CA.

Glaucoma is the leading cause of irreversible blindness, affecting approximately 76 million people worldwide. This optic neuropathy progressively damages the optic nerve, leading to partial or total vision loss. Emerging research identifies neuroinflammation as a key driver of optic neuropathy in glaucoma, but the primary focus of glaucoma therapy today is decreasing the elevated intraocular pressure, the only modifiable risk factor of the disease.

"At Kodiak Sciences, we are leveraging our Antibody Biopolymer Conjugate Drug (ABCD) platform to develop a first-in-class, disease-modifying therapy that decreases the neuroinflammation driving optic neuropathy and simultaneously reduces the elevated intraocular pressure", said Dolly Chang, M.D., Ph.D., Chief Scientific Officer at Kodiak Sciences. "This dual-acting approach has the potential to transform glaucoma treatment by addressing the underlying mechanism of optic nerve damage."

Kodiak's novel "duet" therapy, which will be presented at the Glaucoma 360 New Horizons Forum, directly targets the NLRP3 inflammasome, a key driver of neuroinflammation and optic neuropathy while also incorporating an IOP-lowering molecule to reduce eye pressure. Designed for quarterly dosing, this innovative dual-mechanism investigational therapy is designed to offer a comprehensive and more durable solution to slow glaucoma progression and improve long-term outcomes.

"With the ABCD platform, we aim to redefine glaucoma treatment by delivering next-generation, disease-modifying, multi-mechanism therapies that provide patients with more effective and longer-lasting solutions," Dr. Chang added.